FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087382008> ?p ?o ?g. }

• W2087382008 endingPage "29" @default.
• W2087382008 startingPage "29" @default.
• W2087382008 abstract "Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study Juan Pablo Castanedo-Cazares,1 Gabryela Lárraga-Piñones,1 Adriana Ehnis-Pérez,1 Cornelia Fuentes-Ahumada,1 Cuauhtemoc Oros-Ovalle,2 Bruce R Smoller,3 Bertha Torres-Álvarez11Department of Dermatology, 2Department of Pathology, Hospital Central Dr Ignacio Morones Prieto, Universidad Autónoma de San Luis Potosí, México; 3Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AK, USABackground: Axillary hyperpigmentation is a frequent cause of cosmetic consultations in dark-skinned women from tropical areas, including Latin America. Currently, there is no widely accepted treatment for the disorder, but it is usually treated with bleaching agents because it is considered a variant of inflammatory hyperpigmentation. The purpose of this study was to assess the efficacy of niacinamide 4% and desonide 0.05% emulsions compared with placebo in the treatment of axillary hyperpigmentation.Methods: Twenty-four women aged 19–27 years with hyperpigmented axillae (phototype III–V) were randomly assigned to receive the study treatments in the axillary region. Improvement was assessed at baseline, then clinically and by colorimetry 9 weeks later. Quantitative evaluation including melanin, inflammatory infiltrates, NKI/Beteb, CD1a, CD68, and collagen type IV content was performed by histochemistry and immunohistochemistry, assisted by computerized morphometric analysis.Results: Both niacinamide and desonide induced significant colorimetric improvement compared with placebo; however, desonide showed a better depigmenting effect than niacinamide. A good to excellent response was achieved in 24% of cases for niacinamide, 30% for desonide, and 6% for placebo. We observed a marked disruption of the basal membrane in axillary hyperpigmentation and an inflammatory infiltrate that improved after treatment. Decreased pigmentation in the desonide-treated axillae was associated with recovery of disruption at the basal membrane.Conclusion: Niacinamide and desonide showed depigmenting properties in women with axillary hyperpigmentation. These findings may be explained by their antimelanogenic and anti-inflammatory properties, respectively.Keywords: post-inflammatory hyperpigmentation, niacinamide, desonide" @default.
• W2087382008 created "2016-06-24" @default.
• W2087382008 creator A5005357953 @default.
• W2087382008 creator A5017912541 @default.
• W2087382008 creator A5020398330 @default.
• W2087382008 creator A5022227583 @default.
• W2087382008 creator A5044637112 @default.
• W2087382008 creator A5051174514 @default.
• W2087382008 creator A5076992843 @default.
• W2087382008 date "2013-01-01" @default.
• W2087382008 modified "2023-10-03" @default.
• W2087382008 title "Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study" @default.
• W2087382008 cites W1794591948 @default.
• W2087382008 cites W197307375 @default.
• W2087382008 cites W1996006995 @default.
• W2087382008 cites W2007582870 @default.
• W2087382008 cites W2008266489 @default.
• W2087382008 cites W2008457952 @default.
• W2087382008 cites W2047737653 @default.
• W2087382008 cites W2049774079 @default.
• W2087382008 cites W2052251706 @default.
• W2087382008 cites W2060604544 @default.
• W2087382008 cites W2065124033 @default.
• W2087382008 cites W2071340519 @default.
• W2087382008 cites W2076121443 @default.
• W2087382008 cites W2077277777 @default.
• W2087382008 cites W2080150944 @default.
• W2087382008 cites W2080523870 @default.
• W2087382008 cites W2095289520 @default.
• W2087382008 cites W2123445626 @default.
• W2087382008 cites W2137168733 @default.
• W2087382008 cites W2139901484 @default.
• W2087382008 cites W2142127894 @default.
• W2087382008 cites W2145682122 @default.
• W2087382008 cites W2153752818 @default.
• W2087382008 cites W2160124758 @default.
• W2087382008 cites W2163059346 @default.
• W2087382008 cites W2164721645 @default.
• W2087382008 cites W2170400280 @default.
• W2087382008 cites W23299981 @default.
• W2087382008 cites W2417548397 @default.
• W2087382008 cites W2472113356 @default.
• W2087382008 cites W2406661861 @default.
• W2087382008 doi "https://doi.org/10.2147/ccid.s39246" @default.
• W2087382008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3552481" @default.
• W2087382008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23355788" @default.
• W2087382008 hasPublicationYear "2013" @default.
• W2087382008 type Work @default.
• W2087382008 sameAs 2087382008 @default.
• W2087382008 citedByCount "19" @default.
• W2087382008 countsByYear W20873820082015 @default.
• W2087382008 countsByYear W20873820082017 @default.
• W2087382008 countsByYear W20873820082018 @default.
• W2087382008 countsByYear W20873820082019 @default.
• W2087382008 countsByYear W20873820082020 @default.
• W2087382008 countsByYear W20873820082021 @default.
• W2087382008 countsByYear W20873820082022 @default.
• W2087382008 countsByYear W20873820082023 @default.
• W2087382008 crossrefType "journal-article" @default.
• W2087382008 hasAuthorship W2087382008A5005357953 @default.
• W2087382008 hasAuthorship W2087382008A5017912541 @default.
• W2087382008 hasAuthorship W2087382008A5020398330 @default.
• W2087382008 hasAuthorship W2087382008A5022227583 @default.
• W2087382008 hasAuthorship W2087382008A5044637112 @default.
• W2087382008 hasAuthorship W2087382008A5051174514 @default.
• W2087382008 hasAuthorship W2087382008A5076992843 @default.
• W2087382008 hasBestOaLocation W20873820081 @default.
• W2087382008 hasConcept C141071460 @default.
• W2087382008 hasConcept C142724271 @default.
• W2087382008 hasConcept C16005928 @default.
• W2087382008 hasConcept C181199279 @default.
• W2087382008 hasConcept C204787440 @default.
• W2087382008 hasConcept C27081682 @default.
• W2087382008 hasConcept C2776728111 @default.
• W2087382008 hasConcept C2779728014 @default.
• W2087382008 hasConcept C2780846639 @default.
• W2087382008 hasConcept C2909408332 @default.
• W2087382008 hasConcept C55493867 @default.
• W2087382008 hasConcept C71924100 @default.
• W2087382008 hasConcept C86803240 @default.
• W2087382008 hasConceptScore W2087382008C141071460 @default.
• W2087382008 hasConceptScore W2087382008C142724271 @default.
• W2087382008 hasConceptScore W2087382008C16005928 @default.
• W2087382008 hasConceptScore W2087382008C181199279 @default.
• W2087382008 hasConceptScore W2087382008C204787440 @default.
• W2087382008 hasConceptScore W2087382008C27081682 @default.
• W2087382008 hasConceptScore W2087382008C2776728111 @default.
• W2087382008 hasConceptScore W2087382008C2779728014 @default.
• W2087382008 hasConceptScore W2087382008C2780846639 @default.
• W2087382008 hasConceptScore W2087382008C2909408332 @default.
• W2087382008 hasConceptScore W2087382008C55493867 @default.
• W2087382008 hasConceptScore W2087382008C71924100 @default.
• W2087382008 hasConceptScore W2087382008C86803240 @default.
• W2087382008 hasLocation W20873820081 @default.
• W2087382008 hasLocation W20873820082 @default.
• W2087382008 hasLocation W20873820083 @default.
• W2087382008 hasLocation W20873820084 @default.
• W2087382008 hasOpenAccess W2087382008 @default.

• next